PDEδ-IN-99

PDEδ-IN-99 Suppliers list
Company Name: ShangHai Caerulum Pharma Discovery Co., Ltd.  
Tel: 18149758185 18149758185
Email: sales-cpd@caerulumpharma.com
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 177-54423994 17754423994
Email: 2853530910@QQ.com
Company Name: Shanghai Changyu Medical Technology Co. Ltd.  
Tel: +86-13301875428
Email: sales@changyuhe.com
PDEδ-IN-99 Basic information
Product Name:PDEδ-IN-99
Synonyms:PDEδ-IN-99;N-(4-fluorophenethyl)-4-(4-methyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)butanamide;K-Ras-PDEδ-IN-1;6H-Pyrazolo[3,4-d]pyridazine-6-butanamide, N-[2-(4-fluorophenyl)ethyl]-2,7-dihydro-4-methyl-2-(4-methylphenyl)-7-oxo-;N-(4-Fluorophenethyl)-4-(4-methyl-7-oxo-2-(p-tolyl)-2H-pyrazolo[3,4-d]pyridazin-6(7H)-yl)butanamide;KRasPDEδIN1,PDEδ,cancer,pyrazolopyridazinone-based,inhibit,K Ras PDEδ IN 1,Inhibitor,Phosphodiesterase (PDE);K-Ras-PDEδ-IN-1, 10 mM in DMSO
CAS:1841464-21-8
MF:C25H26FN5O2
MW:447.5
EINECS:
Product Categories:
Mol File:1841464-21-8.mol
PDEδ-IN-99 Structure
PDEδ-IN-99 Chemical Properties
density 1.27±0.1 g/cm3(Predicted)
storage temp. Sealed in dry,Room Temperature
form Solid
pka15.85±0.46(Predicted)
color White to off-white
Safety Information
MSDS Information
PDEδ-IN-99 Usage And Synthesis
UsesK-Ras-PDEδ-IN-1 is a novel and potent competitive K-Ras-PDEδ inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar Kd of 8 nM[1].
in vivo

K-Ras-PDEδ-IN-1 (oral or intraperitoneal injection; 10 mg/kg; single dose) is in different vehicles (A=5% Tween-80, 50% NaCl, 45% H2O; B=20% DMSO, 80% PEG200; C=15% DMSO, 9.5% Cremophor EL/EtOH (1:1), 75.5 % H2O) for oral and intraperitoneal (IP) administration.whereas only very low compound levels are found in plasma after oral dosage, but significantly higher plasma concentrations are found after IP administration in vehicle A, B or C at 10 mg kg[1].K-Ras-PDEδ-IN-1 (intravenous injection; 3 mg kg; single dose; 24 hours) shows a significant increase of the plasma exposure as well as the terminal half-life (t1/2=0.4 hours)when compares to compound 93,exhibits a t1/2, CO, AUC0-tz, AUC0.inf-obs, Clobs, and Vss0-inf-obs values of 4.1 hours, 2790.9 ng/ml, 1646.4 h.ng/ml, 1662.5 h.ng/ml, 1.8 L/h/kg, 5.9 l/kg[1].

IC 50PDE4: 8.3 nM (Kd)
References[1] Sandip Murarka, et al. Development of Pyridazinone Chemotypes Targeting the PDEδ Prenyl Binding Site. Chemistry. 2017 May 2;23(25):6083-6093. DOI:10.1002/chem.201603222
PDEδ-IN-99 Preparation Products And Raw materials
Tag:PDEδ-IN-99(1841464-21-8) Related Product Information
Ro 20-1724 Anti-cancer compound library Apremilast Cilostamide W-7 Hydrochloride Tadalafil